IN THE LATE 1940's Duff and McMillan'
made the remarkable observation that alloxan-diabetic rabbits developed equal or higher blood cholesterol levels, but markedly less atherosclerosis, than did nondiabetic rabbits fed an equivalent high-cholesterol diet. From the excessive visible lipemia characteristic of the alloxan-diabetic rabbits in this experiment, Duff and McMillan surmised that the physical state of blood cholesterol might be altered in the alloxanized animals and that this alteration might account for their lower degree of atherosclerosis.
During those same years, the difficulties attending the study of serum macromolecules in the ultracentrifuge were understood and resolved. 3 The obvious and exciting question presented itself, "Could a similar phenomenon be operative in the human population developing atherosclerosis of such critical arterial sites as the coronary or cerebral beds?" It was evident that such a question had to be studied in the human, for valid concern existed that rabbit atherosclerosis might bear little or no relationship to the stenotic arterial disease responsible for ischemic heart or brain disease in the human.
Two potential avenues of investigation were evident: (1) a study of the relationship of various serum lipoproteins to the occurrence of overt clinical ischemic disease, such as ischemic coronary heart disease; and (2) a study of the relationship of various serum lipoproteins to the degree of intimal arterial narrowing (a key feature of human atherosclerosis). Both avenues had much to commend them; both faced formidable obstacles and extensive requirements on the path to successful execution.
To a large extent, studies of both types have, by now, been completed. Certain apparent paradoxes seem to attend the results. Our purpose herein is to present all the evidence together with a framework which allows for at least a first-order, paradox-free understanding of how the various facets of evidence fit together.
The Relationship of Serum Lipids and Lipoproteins to Overt Clinical
Ischemic Heart Disease
The early premise in this approach was that persons manifesting overt clinical ischemic heart disease at a given point in life must have been developing stenotic coronary artery disease at a greater rate than cohorts not manifesting clinical disease at that same point in life. Ideally, such information must be sought in a prospective study, that is, one in which 679 the "cases" of clinically overt heart disease arise out of an ostensibly healthy substrate sample of the population. Only in this way can it be assured that the "cohorts" truly are such. A study of this type that included measurement of serum cholesterol had been initiated by the United States Public Health Service at Framingham, Massachusetts. In 1950, through the participation of the Donner Laboratory, studies of the low-density lipoproteins in serum were added to the Framingham program. In 1953, a similar study, including serum cholesterol, low-density lipoproteins, and high-density lipoproteins in industrial employees of the Lawrence Radiation Laboratory at Livermore, California, was initiated. The results of 12 years of follow-up in the Framingham study and 10 years in the Livermore study will be presented here.
Retrospective Studies of Clinical
Ischemic Heart Disease Pending the anticipated long period for completion of the prospective studies, it was felt that preliminary insight might be obtained through the study of blood lipoproteins in cases of already established clinical ischemic heart disease, such as survivors of myocardial infarction. The prime advantage was that such cases were immediately available and in reasonably large numbers. But major disadvantages were also present: (1) The possibility that blood lipoprotein status might be nonrepresentative in the postmyocardial infarction period was not readily to be ruled out in an unequivocal manner. (2) Even more distressing, was the inordinate difficulty in assuring a proper choice of cohorts without overt ischemic heart disease. The cases of clinically overt ischemic heart disease came from hospital sources, from physicians' practices, or from the affected individuals still at work in industrial populations under study. Establishment of true "cohorts," including such variables as weight status, lipid status, and blood pressure status, was painful at best, and never really successful. Nevertheless, highly suggestive information did emerge from those early studies, but always with the reservation that the prospective study might alter at least some quantitative aspects of the conclusions. For example, the mean levels of four serum lipoprotein classes, Sf0 0-12, Sf0 12-20, Sfo 20-100, and Sf0 100-400, and of the serum cholesterol were significantly elevated in the clinical ischemic heart disease cases contrasted with "ostensible cohorts," matched by age and sex. -10 A major objective of all such studies was to determine whether, for the human coronary arteries, any particular segment of the entire lipoprotein spectrum was the atherogenic segment or was more atherogenic than bordering segments, as had already been clearly demonstrated for aortic atherogenesis in the rabbit. 12 that this relative importance factor was based upon the study of survivors of myocardial infarction, that the prospective study might very well alter it, and further that some part of the spectrum from Sf0 0 to Sf0 400 might drop out of consideration with respect to provision of an independent contribution to development of disease. 13 Still another difficulty arose early in the study of already established clinical ischemic heart disease. Both for the serum cholesterol measure and for the low-density lipoprotein measures, the difference between overt disease and "ostensible cohorts" decreasd markedly with increasing age of the subjects.", 14 This extremely important feature was itself sorely bedeviled by the "appropriate cohort" problem. Here again, only the prospective studies could be expected to provide resolution and understanding. There were some who inferred from the age-dependent difference that several different diseases were involved, one or several for young subjects, another, or several others, for older subjects.15 Others suggested that the wrong lipid parameters were being measured, and that the proper parameter would not show such an age-dependent relation.'6 Neither of these suggestions has ever appeared reasonable or attractive to the present authors. Indeed, the considerations below will lead to a single unifying concept to explain this agerelated phenomenon, the existence of which has been amply confirmed in the prospective studies. (1) subjects with definite heart disease at entry to the study, and (2) diabetics known to be such at entry. New case3 of heart disease arising in Framingham are provided (in nonduplicative manner) in five categories of ischemic heart disease: (1) myocardial infarction, (2) coronary heart disease (death, but not sudden), (3) coronary insufficiency, (4) sudden death, and (5) angina pectoris. The basis for this reporting system has been described in publications of the broader aspects of the Framingham study. '7-19 While for certain purposes it might be important to use only the group with the apparently strongest manifestation of ischemic heart disease, there is a distinct overriding rationale for combining all cases into one group, labeled "de novo ischemic heart disease" (I.H.D.). The rationale is that the true problem to which we address ourselves is the stated "epidemic of our time-ischemic coronary heart disease," rather than any It should be asked whether some feature As mentioned earlier, a major objective of all such endeavors is to determine for the human lipoprotein spectrum the lower and upper limits with respect to association with ischemic heart disease. Ultimately, it is not enough to prove association of a particular lipoprotein class with the disease; rather, it is necessary to know whether an independent contribution to the association is made by that particular lipoprotein class. In the Framingham data, the Sf°100-400 class is significantly elevated in the 30-39 year old group with de novo ischemic heart disease versus the base population. In no other age category studied could this class be shown to be The observed elevation could be due in part, or even in whole, to interclass correlations. The weakness of segregation power for Sf°100-400 in all other groups suggests that The study of atherosclerosis in autopsy material from subjects whose blood lipid and lipoprotein parameters had been determined during life represents the second major avenue of approach. Such a prospective study has been carried out by Paterson and his coworkers.26 27 Ideally, such studies should cover the same age ranges (30-69 years) as do the prospective studies of the development of de novo clinical ischemic heart disease. The difficulties attendant upon such a study, especially for the younger age groups, are selfevident. Hence, the youngest group available in the Paterson study is the 60-69 year age category. In spite of the limitations in age range, the findings of that study are instructive. 19 and 20) . In the cerebral arteries, the I/E value was proportional to arterial radius over the range of radii existing in that bed. In the coronary arteries, where the average degree of sclerosis in I/E units is higher than that for the cerebral arteries at any particular radius, the linear relationship between I/E and arterial radius existed for radii less than 2.0 mm. Above this radius value, the I/E value did not appear to change with radius at least up to 2.5 mm.
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Certainly no general factor, such as blood lipid level, can explain this radius effect. Range of radius (mm) Note: (I/E ) c = coronary atherosclerosis, where I = intima material area; E = total arterial crosssection area; and c = coronary artery.
Circulation, Volume XXXIV, October 1966 At this juncture it is not necessary to understand how arterial radius comes to be related to intimal sclerosis expressed in I/E units. But the existence of the relationship in arteries of 60-89 year old men is not disputable. Young and associates29 suggested that the radius relation might operate to decelerate the rate of development of new atherosclerosis as the radius of any particular artery is reduced through accumulation of intimal material.
Construction of a Model of Atherogenesis
Let us now consider a simple model of the development of cerebral and coronary intimal sclerosis utilizing the above findings. (1) Assume that atherosclerosis proceeds by concentric reduction of arterial radius. (Actually eccentricity is more common in advanced disease, but we may reserve this consideration as possibly a second-order correction to the model.) (2) Assume that some blood lipid parameter operates as a general factor in all arteries developing sclerosis. (3) Assume that for each artery segment the focal factor can be expressed as a single value.
Thus, let r = radius of lumen of artery at time t, let accumulation of sclerotic intimal material be described in terms of radius reduction, -dr, let k = the focal factor in any particular artery (differing within and between individual subjects), and let c =the value of the pertinent blood lipid parameter (in this first approximation the same blood lipid parameter will be assumed to operate for all arterial beds). Now, explore first the simplest possible de- It is evident that in this relationship, (I/E)t is a function of initial radius r0, and that for particular values of k, c, and t, the degree of sclerosis, (I/E )t increases with increase in r,. Also, the boundary conditions are satisfied, since at t=0, (I/E)0r0 and as t becomes very large, (I/E)t approaches 1, which expresses complete luminal obliteration by intimal sclerosis. I/E can never become greater than 1.0.
Validity of the Model of Atherogenesis
We may now explore whether this simple relationship fits: (1) the de novo ischemic heart disease findings of Framingham and Livermore, (2) the Paterson findings concerning blood lipids and coronary sclerosis in 60-69 year old men, and (3) the observations of Young and associates relating arterial radius to I/E values.
As a first approximation, this test was done with the following simplifications:
Let c = 5 represent the median value of the blood lipid parameter and assume no age dependence for the blood lipid parameter itself.
Let the process start, arbitrarily, at age 25 years. After preliminary trials of appropriate k values, a value of k 0.01 was selected, and I/E values were calculated as a function of c, t, and ro, using the integrated form of equation 2. In figure 1 are presented the calculations for I/E in an artery of r0 =2.0 mm, as a function of blood lipid parameter and age. In figure 2 are presented the calculations for I/E as a function of initial arterial radius and age, at the median value for the blood lipid parameter, c 5. Consideration of these figures allows exploration of where this simple model fits reality and where it does not.
1. From figure 1 it is noted that in early years after inception of the process, the degree of sclerosis differs appreciably with change in value of c, the blood lipid parameter. Progressively with age, the degree of sclerosis, AGE (yrs.) Figure 1 Circulation, Volume figure 2) , as observed by Young and associates. A major disagreement with reality in figure  1 is that the predicted degree of coronary sclerosis (I/E) approaches values of 0.9 to 1.00, which is at variance with the observations of Young and associates. Lowering of the value chosen for k will improve this aspect of the model, but will worsen the agreement of the calculated values both with the data on incidence of ischemic heart disease and with the Paterson studies of degree of sclerosis in relation to blood lipid parameters. However, if k itself is allowed to decrease as appreciable atherosclerosis develops, the only major disagreement with reality is removed. Examination of atherosclerosis in autopsy material reveals in general that new sclerosis is not the rule over the "fibrous cap" commonly described in moderately advanced lesions. This observation would be consistent with a decrease in k as atherosclerosis becomes appreciable, over and above the radius effect itself.
A simple function expressing the decline in k with appreciable development of atherosclerosis is the following: k = ko e-m(I/E)2 October 1966 means in subjects beyond 50 years of age can hardly be expected to alter the risk of de novo development of ischemic heart disease.
Over a wide range of blood lipid parameters, the data and concepts presented herein indicate no appreciable difference in risk for subjects who are over 50 years of age. Thus, it is hardly likely that alterations of blood lipid parameters within this range can produce measurable alteration in risk.
It is essential to qualify this prediction lest it be misunderstood. A dietary regimen or a pharmaceutical agent may influence the disease by other means than via effects upon blood lipid parameters. Prediction 4 is necessarily silent about effects other than those related to blood lipid parameters.
Prediction 5. If dietary and pharmacological alteration of blood lipid parameters cannot be expected to alter the risk in ostensibly healthy subjects over 50 years old, there is no reason to expect that such measures will alter the risk for persons with established ischemic heart disease.
Two recent controlled studies, one with low fat diets33 and the other with corn oil supplements,34 indicate no suggestion that such measures alter prognosis in established ischemic heart disease. Prediction 6. If moderate reduction in blood lipid parameters does prove to alter the risk of de novo ischemic heart disease in ostensibly healthy subjects of young age groups (well below 55 years of age), the effect will be lost when the subjects reach 55 years of age, even if the regimen prescribed is adhered to faithfully. In essence this is a statement that the life expectancy at 55 years of age and beyond will not be materially altered, so far as coronary disease is concerned, by moderate reductions in blood lipid levels within the range of values characteristic of the U.S. population at present. Prediction 7. If longevity as limited by coronary atherosclerosis is to be altered through effects upon blood lipid parameters, a drastic rather than moderate reduction in such parameters is required. (Note effect of a value of 1.0 in figure 5 .)
At present, we do not know how to provoke such drastic alteration in blood lipids, nor do we know whether such drastic lowerings are otherwise consistent with health. A small proportion of the U.S. population is spontaneously characterized by extremely low blood lipid levels and appears to enjoy good health. Such individuals deserve intensive study if clinical use is ever to be made of drastic lowering of serum lipoproteins or cholesterol.
Prediction 8. The k value, expressing the focal determinant of development of atherosclerosis deserves intensive study. At present we have essentially no information concerning factors that may reduce the value of k or how it comes to have the value it does have. It is clear that k differs within segments of a single artery, between arteries in a single individual, and between individuals in the population for a particular artery. It is not inconceivable that a concerted attack upon understanding k may be more rewarding than efforts to alter blood lipid parameters.
Prediction 9. All the findings discussed herein pertain to blood lipid parameters as they exist in free-living population samples studied in the United States. Specifically, they refer to two samples, at Framingham and at Livermore. It is conceivable that alteration in composition of blood lipoproteins, as suggested by Geer and McGill35 might lead to alterations in development of atherosclerosis even though no alteration in absolute lipoprotein levels occurred. A priori, a particular alteration may be possible for better, for worse, or for no change with respect to atherogenesis. Certainly the burden of proof that any alteration in composition is beneficial rests upon those proposing such alteration.
Prediction 10. In the absence of significant progress in beneficial alteration of k values or of ability to produce safe widespread drastic lowering of serum lipids, it would appear highly desirable to devote major attention to the acute determinants of myocardial infarction or other clinical manifestations of coronary heart disease rather than to coronary atherogenesis itself.
